statin induced myopathy and myalgia time trend analysis and comparison of risk associated with statin class from 1991–2006他汀类药物诱导肌病和肌痛时间趋势分析和比较相关的风险与他汀类从1991 - 2006.pdfVIP

下载本文档

1
0
约6.81万字
约 9页
2017-09-12 发布于上海
举报
版权申诉

statin induced myopathy and myalgia time trend analysis and comparison of risk associated with statin class from 1991–2006他汀类药物诱导肌病和肌痛时间趋势分析和比较相关的风险与他汀类从1991 - 2006.pdf

1、本文档共9页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

statin induced myopathy and myalgia time trend analysis and comparison of risk associated with statin class from 1991–2006他汀类药物诱导肌病和肌痛时间趋势分析和比较相关的风险与他汀类从1991 - 2006

Statin Induced Myopathy and Myalgia: Time Trend Analysis and Comparison of Risk Associated with Statin Class from 1991–2006 1 2 3 4 Mariam Molokhia *, Paul McKeigue , Vasa Curcin , Azeem Majeed 1 Department of Epidemiology Population Health, London School of Hygiene Tropical Medicine, London, United Kingdom, 2 Public Health Sciences, University of Edinburgh Medical School, Edinburgh, United Kingdom, 3 Department of Computing, Imperial College London, London, United Kingdom, 4 Department of Primary Care and Social Medicine, Imperial College, London, United Kingdom Abstract Background: Statins are widely used as a cholesterol lowering medication, reduce cardiovascular mortality and morbidity in high risk patients; and only rarely cause serious adverse drug reactions (ADRs). UK primary care databases of morbidity and prescription data, which now cover several million people, have potential for more powerful analytical approaches to study ADRs including adjusting for confounders and examining temporal effects. Methods: Case-crossover design in detecting statin associated myopathy ADR in 93, 831 patients, using two independent primary care databases (1991–2006). We analysed risk by drug class, by disease code and cumulative year, exploring different cut-off exposure times and confounding by temporality. Results: Using a 12 and 26 week exposure period, large risk ratios (RR) are associated with all classes of statins and fibrates for myopathy: RR 10.6 (9.8–11.4) and 19.9 (17.6–22.6) respectively. At 26 weeks, the largest risks are with fluvastatin RR 33.3 (95% CI 16.8–66.0) and ciprofibrate (with previous statin use) RR 40.5 (95% CI 13.4–122.0). AT 12 weeks the differences between cerivastatin and atorvastatin RR for myopathy were found to be sign